Incretin hormones importantly enhance postprandial insulin secretion but are rapidly
degraded to inactive metabolites by ubiquitous dipeptidyl peptidase IV. The concentrations …

OBJECTIVE—To evaluate the effects of metformin on glucagon-like peptide 1 (GLP-1) and
leptin levels. RESEARCH DESIGN AND METHODS—A total of 10 obese nondiabetic male …

Incretin hormones are insulinotropic hormones from the intestinal mucosa, which after being
released in response to ingestion of a meal, enhance insulin secretion in excess of that …

Postprandial release of the incretin glucagon-like peptide-1 (GLP-1) has been suggested to
act as an endogenous satiety factor in humans. In rats, however, the evidence for this is …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
27586228&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Novel therapeutic regimens are provided which comprise the administration of
therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes …

Glucose-dependent insulinotropic peptide (GIP) is known to be degraded by dipeptidyl
peptidase IV (DPP IV), forming an inactive metabolite, but the extent of the enzyme's role in …

OBJECTIVE—The incretin hormone glucagon-like peptide-1 (GLP-1) reduces plasma
glucose in type 2 diabetic patients by stimulating insulin secretion and inhibiting glucagon …

Aims It has previously been shown that intravenous and subcutaneous administration of
glucagon‐like peptide (GLP)‐1 concomitant with intravenous glucose results in reactive …

Glucagon is a 29-amino acid polypeptide released from pancreatic islet α-cells that acts to
maintain euglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Despite …